About this Medicine article
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study by Burris, Howard A; Flinn, Ian W; Patel, Manish R; Fenske, Timothy S; Deng, Changchun; Brander, Danielle M; Gutierrez, Martin; Essell, James H; Kuhn, John G; Miskin, Hari P; Sportelli, Peter; Weiss, Michael S; Vakkalanka, Swaroop; Savona, Michael R; O'Connor, Owen A is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Burris, Howard A; Flinn, Ian W; Patel, Manish R; Fenske, Timothy S; Deng, Changchun; Brander, Danielle M; Gutierrez, Martin; Essell, James H; Kuhn, John G; Miskin, Hari P; Sportelli, Peter; Weiss, Michael S; Vakkalanka, Swaroop; Savona, Michael R; O'Connor, Owen A
- Publisher
- The Lancet; Elsevier ; The Lancet Publishing Group; Elsevier BV (ISSN 1470-2045)
- Published
- 2018
- Language
- EN
- Field
- Medicine (Health Sciences)